Announcements Trials
Browse Landscape

Phase

Phase 2 39Phase 1 18Phase 1/2 9Phase 3 7Phase EARLY_PHASE1 3Phase 2/3 2

Status

Unknown 4Completed 4Recruiting 2Not yet recruiting 2Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioblastoma 2Gliosarcoma 1

Interventions

Cisplatin 13Paclitaxel 11Cyclophosphamide 11Doxorubicin 10Magnetic Resonance Spectroscopy 9Prednisone 8Gemcitabine 8Docetaxel 8Specimen Handling 7Oxaliplatin 7Carboplatin 7Vincristine 6Etoposide 6Capecitabine 6pembrolizumab 5Rituximab 5Radiotherapy 5Leucovorin 5Cytarabine 5Bevacizumab 5atezolizumab 4Trastuzumab 4Platinum 4Nivolumab 4Fluorouracil 4Dexamethasone 4Biopsy 41,2-diaminocyclohexaneplatinum II citrate 4Watchful Waiting 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Active not recruiting × Temozolomide × Clear all
NCT02152982 2026-04-28

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
447 enrolled 20 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT06105619 2026-01-20

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

Beijing Pearl Biotechnology Limited Liability Company

Phase 2/3 Active not recruiting
84 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡